Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
This Form 144 filing indicates that an unidentified holder of Takeda Pharmaceutical Company Limited (TAK) American Depositary Shares (ADSs) plans to sell up to 5,608 ADSs through Interactive Brokers on or about 9 July 2025 on the NYSE. The block is valued at roughly $86,475 based on the market price reported in the form. The shares derive from restricted-stock-unit awards that vested on 1 July 2025. With 123.49 million ADSs outstanding, the proposed sale represents only about 0.0045 % of the float, implying immaterial dilution or trading-volume impact. No other sales have been made by the filer in the past three months, and the signer certifies the absence of undisclosed adverse information. While insider sales occasionally raise sentiment concerns, the size and routine compensation origin suggest limited market significance.
Takeda Pharmaceutical Company Limited (TAK) has filed a Form 6-K confirming completion of the previously announced disposal of treasury shares for its Long-Term Incentive Plan (LTIP) covering employees outside Japan.
- Shares disposed: 17,270,941 common shares (down 84,829 shares from the June 10 plan).
- Disposal price: ¥4,336 per share.
- Total value: ¥74,886,800,176 (approximately ¥368 million less than originally anticipated).
- Payment date: 8 July 2025 (unchanged).
- Participants: 10,283 employees (previously 10,346).
The change reflects the partial forfeiture of rights by certain allottees. Management states the adjustment will have an immaterial impact on FY 2025 financial results (fiscal year ending 31 Mar 2026). Because the shares come from existing treasury stock, the transaction generates no cash inflow but modestly increases the public float, implying potential dilution of roughly 1 % of total shares outstanding. Strategically, the action completes Takeda’s equity-based compensation initiative, intended to improve employee alignment with shareholder interests, and has no effect on guidance or core operations.
Takeda Pharmaceutical Company Limited (NYSE: TAK) filed a Form 6-K to furnish debt-financing exhibits related to two new U.S. dollar bond offerings issued through its subsidiary, Takeda U.S. Financing, Inc. The exhibits include the master Indenture dated 2 July 2025 and specimen note forms for:
- $1.65 billion 5.200% Guaranteed Senior Notes due 2035
- $750 million 5.900% Guaranteed Senior Notes due 2055
Legal opinions from Sullivan & Cromwell LLP and Nishimura & Asahi covering the validity of the notes are also provided. All exhibits are incorporated by reference into the company’s shelf Registration Statement on Form F-3 (File Nos. 333-288301 & 333-288301-01) filed on 25 June 2025. The filing contains no additional financial results or strategic commentary beyond the documentation of these debt instruments.
Takeda Pharmaceutical (NYSE:TAK) has filed its annual Form 20-F report for foreign issuers. The filing appears to be a standard annual report containing detailed financial information, segment performance data, and regulatory disclosures across their pharmaceutical product portfolio including key drugs like Entyvio, Takhzyro, and Vyvanse. The report includes comprehensive breakdowns of revenue by therapeutic areas including Gastroenterology, Rare Diseases, PDT (Plasma-Derived Therapies), Oncology, Vaccines, and Neuroscience segments.
Takeda Pharmaceutical Company Limited (NYSE:TAK) filed a Form 6-K reporting the outcome of its 149th Annual Meeting of Shareholders and subsequent Board of Directors meeting held on 25 June 2025. The filing focuses exclusively on corporate governance matters and contains no financial performance data.
Board composition: The Board remains at 14 members, of which 11 (≈79%) are external directors. An external director, Masami Iijima, continues to chair the Board, underscoring Takeda’s commitment to independent oversight.
Key assignments (effective 25 June 2025):
- Christophe Weber retains dual roles as Representative Director and President & CEO.
- Milano Furuta remains Director & CFO; Andrew Plump continues as Director, President, R&D.
- Audit & Supervisory Committee: Headed by Koji Hatsukawa with three additional external members; all are within their two-year tenure and were not up for re-election.
- Nomination Committee: Six external directors; chaired by Masami Iijima. CEO Christophe Weber attends as observer only.
- Compensation Committee: Five external directors; chaired by Emiko Higashi.
Governance implications: Committees composed solely of independent directors, coupled with an external board chair, align with best-practice governance standards designed to enhance transparency, mitigate conflicts of interest, and safeguard minority shareholder rights. No changes were announced to strategic direction, capital allocation, or executive compensation structures beyond committee assignments.
Takeda Pharmaceutical held its 149th Annual General Meeting of Shareholders on June 25, 2025, where several key resolutions were passed. The meeting addressed the company's performance for FY2024 (April 1, 2024 to March 31, 2025).
Key resolutions approved include:
- Approval of a year-end dividend of 98 JPY per share
- Re-election of ten Directors not serving on the Audit and Supervisory Committee, including CEO Christophe Weber and seven External Directors
- Approval of executive bonuses totaling up to 460 million JPY for two eligible Directors (excluding overseas Directors and External Directors)
The meeting also reviewed the Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements, along with audit results from the Accounting Auditor and Audit and Supervisory Committee. This filing demonstrates Takeda's commitment to corporate governance and shareholder transparency.
FAQ
What is the current stock price of Takeda Pharm (TAK)?
What is the market cap of Takeda Pharm (TAK)?
